Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RHEB | Q15382 | 9/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.42 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.40 |
| ▸ | PLAU | P00749 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | NSD2 | O96028 | 1/20 | 0.38 |
| ▸ | AS3MT | Q9HBK9 | 1/20 | 0.38 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16632497 | 0.86 | SRD5A2 (0.40) | SRD5A2NSD2AS3MTSGMS2 | |
| SCHEMBL16632405 | 0.86 | SRD5A2 (0.52) | SRD5A2SCN9ANSD2AS3MT | |
| SCHEMBL16634433 | 0.81 | RHEB (0.70) | RHEBSLC6A4SRD5A2PLAU | |
| SCHEMBL9593980 | 0.80 | SRD5A2 (0.60) | SRD5A2NSD2AS3MT | |
| SCHEMBL16632563 | 0.80 | RHEB (0.45) | RHEBSLC6A4SRD5A2PLAU | |
| SCHEMBL16632427 | 0.76 | SRD5A2 (0.53) | RHEBSRD5A2 | |
| SCHEMBL16632334 | 0.76 | L3MBTL1 (0.45) | RHEB | |
| SCHEMBL23709592 | 0.71 | RHEB (0.81) | RHEBSLC6A4SRD5A2PLAU | |
| SCHEMBL5538708 | 0.69 | MAPT (0.63) | — | |
| SCHEMBL18865570 | 0.67 | PLAU (0.54) | SLC6A4PLAUSGMS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9382245-B2 | Compounds and methods for treating HIV infections | YALE UNIVERSITY (US) | 2016-07-05 | — | — | US | disclosed |
| US-20150105351-A1 | COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105351-A1 | COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS | POLM, POLRMT, DHFR | RHEB 2503/4885SLC6A4 4266/4885SRD5A2 1884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.